Compass Pathways plc Depositary Receipt (CMPS)
Summary
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Compass Pathways plc Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 304 | $2,636.31 | $3,629.76 | $993.45 | 37.68% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 46 | $254.38 | $539.58 | $285.2 | 112.12% |
 John H. Burbank III Passport Capital LLC | 2.34M | $12.97M | $27.55M | $14.58M | 112.48% |
 Didric Cederholm Lion Point Capital LP | 80,000 | $454,000 | $940,000 | $486,000 | 107.05% |
| YA Yinka Akinsola Blue Trust Inc. | 310 | $1,345.8 | $3,617.7 | $2,271.9 | 168.81% |
Compass Pathways plc Depositary Receipt Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| FB Francois Brisebois Oppenheimer | 15,337.42 | $199,233.13 | $182,975.46 | -$16,257.67 | -8.16% |
Compass Pathways plc Depositary Receipt (CMPS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Compass Pathways plc Depositary Receipt ever had a stock split?
Compass Pathways plc Depositary Receipt Profile
| Health Care Technology Industry | Healthcare Sector | Kabir Kumar Nath CEO | NASDAQ (NGS) Exchange | 20451W101 CUSIP |
| GB Country | 156 Employees | - Last Dividend | - Last Split | 18 Sep 2020 IPO Date |
Overview
COMPASS Pathways plc operates as a mental health care company with operational bases in the United Kingdom and the United States. It focuses on developing innovative therapies for mental health conditions that are difficult to treat with conventional methods. Originally known as COMPASS Rx Limited, the company underwent a name change to COMPASS Pathways plc in August 2020. Since its incorporation in 2020, COMPASS Pathways has been at the forefront of mental health care, endeavoring to address some of the most challenging aspects of psychiatric conditions through cutting-edge research and clinical trials. The company's headquarters are located in London, the United Kingdom, positioning it strategically in a hub of medical research and technological advancement.
Products and Services
- COMP360 Psilocybin Therapy
COMP360 represents COMPASS Pathways' flagship product, a psilocybin-based therapeutic solution currently undergoing clinical trials. Conceptualized as a potential game-changer in the treatment of mental health conditions, COMP360 is designed to target illnesses that have traditionally been resistant to treatment. The therapy is in Phase III clinical trials for treating treatment-resistant depression, marking a significant step forward in addressing this pervasive and debilitating condition. Moreover, COMP360 is not limited to treating depression; it is also in Phase II clinical trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. These trials underscore COMPASS Pathways' commitment to diversifying the potential applications of psilocybin therapy, aiming to offer hope to patients with varying mental health challenges.
